Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Matcha, a finely ground powder of specially grown and processed green tea leaves, has gained attention for its potential cardiovascular benefits. Scientific interest in matcha’s effect on cardiovascular disease (CVD) stems from its high concentration of catechins, particularly epigallocatechin gallate (EGCG), a potent antioxidant. Multiple epidemiological and clinical studies on green tea—of which matcha is a concentrated form—suggest that regular consumption is associated with reduced risk of CVD. Proposed mechanisms include lowering LDL cholesterol, reducing blood pressure, improving endothelial function, and decreasing oxidative stress and inflammation, all of which are key factors in cardiovascular health.

Randomized controlled trials have shown that green tea catechins can modestly lower LDL cholesterol and total cholesterol, and some meta-analyses suggest a reduction in blood pressure among habitual green tea drinkers. However, direct studies on matcha itself are limited; most evidence is extrapolated from broader research on green tea. Nonetheless, matcha provides higher concentrations of catechins and L-theanine, which may enhance these effects.

While the evidence is promising and biologically plausible, more large-scale, long-term clinical trials specifically assessing matcha’s impact on cardiovascular outcomes are needed. Therefore, the current scientific support is moderate (3/5), with most recommendations based on green tea studies rather than matcha exclusively. Regular matcha consumption may be reasonable as part of a heart-healthy diet, but should not replace standard medical therapies for CVD.

More about matcha
More about Cardiovascular Disease

Other ingredients used for Cardiovascular Disease

Other health conditions supported by matcha

Products containing matcha